scispace - formally typeset
Journal ArticleDOI

Advances in the development of new tuberculosis drugs and treatment regimens

TLDR
Current concepts and recent advances in TB drug discovery and development are covered, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.
Abstract
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.

read more

Citations
More filters
Journal ArticleDOI

Towards tuberculosis elimination: an action framework for low-incidence countries

Knut Lönnroth, +72 more
TL;DR: An action framework for countries with low tuberculosis (TB) incidence sets out priority interventions required for these countries to progress first towards “pre-elimination” and eventually the elimination of TB as a public health problem.
Journal ArticleDOI

Antibiotics in the clinical pipeline in 2013

TL;DR: The continued emergence of multi-drug-resistant bacteria is a major public health concern and the identification and development of new antibiotics, especially those with new modes of action, is imperative to help treat these infections.
Journal ArticleDOI

Heterogeneity in tuberculosis

TL;DR: This Review draws on model systems and human data to discuss multiple facets of TB biology and their relationship to the overall heterogeneity observed in the human disease.
References
More filters
Journal ArticleDOI

Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country

TL;DR: The global burden of tuberculosis remains enormous, mainly because of poor control in Southeast Asia, sub-Saharan Africa, and eastern Europe, and because of high rates of M tuberculosis and HIV coinfection in some African countries.
Journal ArticleDOI

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

TL;DR: A diarylquinoline, R207910, is identified that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Journal ArticleDOI

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

TL;DR: MDR tuberculosis is more prevalent than previously realised in a rural area in KwaZulu Natal, South Africa and has been transmitted to HIV co-infected patients and is associated with high mortality.
Journal ArticleDOI

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

TL;DR: The biology of latent tuberculosis is discussed as part of a broad range of responses that occur following infection with Mycobacterium tuberculosis, which result in the formation of physiologically distinct granulomatous lesions that provide microenvironments with differential ability to support or suppress the persistence of viable bacteria.
Related Papers (5)